Proteostasis' doublet CF therapy improves lung function in Phase I

Proteostasis Therapeutics Inc. (NASDAQ:PTI) reported that its doublet cystic fibrosis therapy improved percent predicted forced expiratory volume in 1 second (ppFEV1) and sweat chloride levels in a Phase I trial. The doublet therapy comprised CF transmembrane conductance regulator (CFTR) corrector PTI-801 and CFTR potentiator

Read the full 444 word article

User Sign In